Table of contents
March 2007 Vol 7 No 3
From the editors
p155 | doi:10.1038/nrc2097
Research Highlights
Therapy: Restoration
p157 | doi:10.1038/nrc2099
Genetics: All in the family
p158 | doi:10.1038/nrc2098
Signalling pathways: Collusion
p158 | doi:10.1038/nrc2100
Tumour immunotherapy: Shifting the balance
p158 | doi:10.1038/nrc2101
Tumorigenesis: Dissecting the instabilities
p159 | doi:10.1038/nrc2095
Cancer stem cells: The environment matters
p160 | doi:10.1038/nrc2092
Trial Watch
Window of opportunity
p160 | doi:10.1038/nrc2102
Chromosomal instability: Going to any length
p161 | doi:10.1038/nrc2093
Tumour suppressors: Floxed foxes
p161 | doi:10.1038/nrc2094
Tumorigenesis: PTEN — a new guardian of the genome
p162 | doi:10.1038/nrc2096
In the news
Genetic test gets FDA approval
p162 | doi:10.1038/nrc2103
Chemoresistance: Priming resistance
p162 | doi:10.1038/nrc2105
In brief
In Brief
p163 | doi:10.1038/nrc2104
Progress
The p53 family in differentiation and tumorigenesis
Thorsten Stiewe
p165 | doi:10.1038/nrc2072
Are members of the p53 family of transcription factors able to influence tumour development by regulating cellular differentiation?
Reviews
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman & Daniel A. Haber
p169 | doi:10.1038/nrc2088
The lessons learned from the clinical application of epidermal growth factor receptor tyrosine kinase inhibitors provide important insights for lung cancer therapies. What approaches might circumvent the rapid acquisition of resistance and increase the efficacy of targeted therapies in lung cancer and other epithelial cancers?
The Salvador–Warts–Hippo pathway — an emerging tumour-suppressor network
Kieran Harvey & Nicolas Tapon
p182 | doi:10.1038/nrc2070
The Salvador–Warts–Hippo (SWH) pathway is involved in tissue growth control in Drosophila melanogaster. There is increasing evidence that deregulation of this conserved pathway occurs in human tumours. What insights do the studies in Drosophila provide for human carcinogenesis?
Candidate mechanisms for chemotherapy-induced cognitive changes
Tim A. Ahles & Andrew J. Saykin
p192 | doi:10.1038/nrc2073
Cancer patients often experience cognitive changes after chemotherapy (sometimes called "chemo brain"). What are some possible molecular mechanisms for this detrimental side effect of cancer therapy?
Inhibiting transient protein–protein interactions: lessons from the Cdc25 protein tyrosine phosphatases
Johannes Rudolph
p202 | doi:10.1038/nrc2087
Transient protein–protein interactions occur in many cellular processes that are implicated in cancerous growth, such as cell-cycle transitions mediated by the cell division cycle 25 phosphatases. What are the issues that are encountered when considering these transient interactions as drug targets?
Perspective
Opinion
Darwinian medicine: a case for cancer
Mel Greaves
p213 | doi:10.1038/nrc2071
As we have evolved, we have aquired several evolutionary traits that might increase our susceptibility to cancer development. Mel Greaves outlines the benefits of a Darwinian view of cancer biology, cause and treatment.
